Chemotherapy-Related Cardiovascular Complications

  • Muzna Hussain
  • Patrick CollierEmail author
Reference work entry


This book chapter addresses chemotherapy-related cardiovascular complications that may result in admission of oncology patients to the intensive care. It is covered in a systematic way from etiology, epidemiology, pathophysiology, and clinical features to diagnosis, management, and prognosis. Because many oncology patients undergo concomitant chemotherapy and radiotherapy which may have additive cardiovascular toxicity, the term cancer therapeutics is increasingly being used to encompass these exposures. There has been an exponential rate of growth in the development of new cancer therapeutics, often with more complex mechanism of actions. There is an increasing recognition of a myriad of secondary acute cardiovascular complications, some of which may be quite rare and therefore not identified or reported until the therapy is already approved and administered to the larger general population. Oncology patients may find themselves admitted to the intensive care because of a cardiac diagnosis that is independent of, partly related to, or directly as a consequence of their prior or current cancer therapy. It is imperative therefore for the patient/their healthcare power of attorney and the treating healthcare professional to be aware of such a potential etiology, to report this as part of thorough history taking, and to explore the potential relationship between the therapy and the illness. This is because the pathophysiology, clinical features, diagnosis, and prognosis can all be strikingly different depending on whether the cancer therapy is implicated in the etiology. Similarly, it can influence whether a cancer therapy is contraindicated for that patient in the future.


Cancer therapeutics Cardiovascular complications Chemotherapy Critical care Oncology 


  1. 1.
    US Department of Health and Human Services, N.I.o.H., National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017.Google Scholar
  2. 2.
    Taccone FS, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(1):R15.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Polk A, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–84.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67.CrossRefGoogle Scholar
  5. 5.
    Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26(2):E18–20.PubMedGoogle Scholar
  6. 6.
    Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47.CrossRefGoogle Scholar
  7. 7.
    Sharalaya Z. Collier P. Prevention of cardiotoxicities with traditional and novel chemotherapeutic agents. Curr Heart Fail Rep. 2018;15(4):260–269.Google Scholar
  8. 8.
    Hidalgo S, Albright CA, Wells GL. A case of trastuzumab-associated cardiomyopathy presenting as an acute coronary syndrome: acute trastuzumab cardiotoxicity. Case Rep Cardiol. 2013;2013:473979.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Hamirani Y, et al. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Med Oncol. 2016;33(7):82.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Donnellan E, et al. Radiation-induced heart disease: a practical guide to diagnosis and management. Cleve Clin J Med. 2016;83(12):914–22.CrossRefGoogle Scholar
  11. 11.
    Alam S, et al. Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series. Case Rep Oncol. 2018;11(1):221–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Alexandre J, et al. Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms. Pharmacol Ther. 2018;189:89–103.CrossRefGoogle Scholar
  13. 13.
    Wiczer TE, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1(20):1739–48.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lampson BL, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017;129(18):2581–4.CrossRefGoogle Scholar
  15. 15.
    Pallazola VA, et al. Anthracycline-induced acute myocarditis and ventricular fibrillation arrest. Am J Hematol. 2018;93(3):469–70.CrossRefGoogle Scholar
  16. 16.
    Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mahmood SS, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yoshikawa T. Takotsubo cardiomyopathy, a new concept of cardiomyopathy: clinical features and pathophysiology. Int J Cardiol. 2015;182:297–303.CrossRefGoogle Scholar
  20. 20.
    Gopalakrishnan M, et al. Predictors of short- and long-term outcomes of Takotsubo cardiomyopathy. Am J Cardiol. 2015;116(10):1586–90.CrossRefGoogle Scholar
  21. 21.
    Coen M, et al. Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature. BMC Cancer. 2017;17(1):394.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sundaravel S, et al. FOLFOX induced Takotsubo cardiomyopathy treated with impella assist device. Case Rep Cardiol. 2017;2017:8507096.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Oshima Y, et al. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese adverse drug event report database. Circulation. 2017;135(8):815–7.CrossRefGoogle Scholar
  25. 25.
    Agrawal V, Christenson ES, Showel MM. Tyrosine kinase inhibitor induced isolated pericardial effusion. Case Rep Oncol. 2015;8(1):88–93.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    de Lavallade H, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745–7.CrossRefGoogle Scholar
  27. 27.
    Al-Hawwas M, et al. Acute coronary syndrome management in cancer patients. Curr Oncol Rep. 2018;20(10):78.CrossRefGoogle Scholar
  28. 28.
    Meyer CC, et al. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17(4):729–36.PubMedGoogle Scholar
  29. 29.
    Von Hoff DD, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.CrossRefGoogle Scholar
  30. 30.
    Doroshow JH. Doxorubicin-induced cardiac toxicity. N Engl J Med. 1991;324(12):843–5.CrossRefGoogle Scholar
  31. 31.
    Chatterjee K, et al. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155–62.CrossRefGoogle Scholar
  32. 32.
    Lefrak EA, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302–14.CrossRefGoogle Scholar
  33. 33.
    Desai MY, et al. Radiation-associated cardiac disease: a practical approach to diagnosis and management. JACC Cardiovasc Imaging. 2018;11(8):1132–49.CrossRefGoogle Scholar
  34. 34.
    Zang J, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7(2):e30353.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Chu TF, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Rini BI, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–73.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    De Botton S, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1998;92(8):2712–8.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Larrea L, et al. Cardiac tamponade and cardiogenic shock as a manifestation of all-trans retinoic acid syndrome: an association not previously reported. Haematologica. 1997;82(4):463–4.PubMedGoogle Scholar
  39. 39.
    Polk A, et al. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Zhang S, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42.CrossRefGoogle Scholar
  41. 41.
    Tan TC, et al. Anthracycline-induced cardiomyopathy in adults. Compr Physiol. 2015;5(3):1517–40.CrossRefGoogle Scholar
  42. 42.
    Ferreira de Souza T, et al. Anthracycline therapy is associated with cardiomyocyte atrophy and preclinical manifestations of heart disease. JACC Cardiovasc Imaging. 2018;11(8):1045–55.CrossRefGoogle Scholar
  43. 43.
    Telli ML, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25(23):3525–33.CrossRefGoogle Scholar
  44. 44.
    Sengupta PP, et al. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc. 2008;83(2):197–203.CrossRefGoogle Scholar
  45. 45.
    de Korte MA, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43(14):2046–51.CrossRefGoogle Scholar
  46. 46.
    Fedele C, et al. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat. 2012;134(2):595–602.CrossRefGoogle Scholar
  47. 47.
    Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075–80.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–56.CrossRefGoogle Scholar
  49. 49.
    Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Laza AJ, Wargo JA, Davies MA. Comparative immune analysis of autoimmune myocarditis from ipilimumab. Oncoimmunology. 2017;6:e1361097.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Laubli H, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Carver JR, et al. Myocarditis during lenalidomide therapy. Ann Pharmacother. 2010;44(11):1840–3.CrossRefGoogle Scholar
  52. 52.
    Komamura K, et al. Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment. World J Cardiol. 2014;6(7):602–9.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Boland TA, Lee VH, Bleck TP. Stress-induced cardiomyopathy. Crit Care Med. 2015;43(3):686–93.CrossRefGoogle Scholar
  54. 54.
    Yusuf SW, et al. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–50.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Sulpher J, et al. Acute cardiogenic shock induced by infusional 5-fluorouracil. Case Rep Oncol Med. 2014;2014:819396.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Mant J, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13(32):1–207.. iiiCrossRefGoogle Scholar
  57. 57.
    Caforio AL, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–48.. 2648a–2648dCrossRefGoogle Scholar
  58. 58.
    Templin C, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–38.CrossRefGoogle Scholar
  59. 59.
    Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–64.CrossRefGoogle Scholar
  60. 60.
    Reichlin T, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med. 2012;125(12):1205–1213 e1.CrossRefGoogle Scholar
  61. 61.
    Ganatra S, Sharma A, Levy MS. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc Interv. 2017;10(22):2334–7.CrossRefGoogle Scholar
  62. 62.
    Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.CrossRefGoogle Scholar
  63. 63.
    Shah SR, Park K. Long QT syndrome: a comprehensive review of the literature and current evidence. Curr Probl Cardiol. 2019;44(3):92–106.CrossRefGoogle Scholar
  64. 64.
    Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295–316.CrossRefGoogle Scholar
  65. 65.
    Duan J, et al. Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives. Oncotarget. 2018;9(39):25738–49.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;43(1):1–3.CrossRefGoogle Scholar
  67. 67.
    Peigne V, et al. Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med. 2009;35(3):512–8.CrossRefGoogle Scholar
  68. 68.
    Velders MA, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013;112(12):1867–72.CrossRefGoogle Scholar
  69. 69.
    Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006;58(4):487–93.CrossRefGoogle Scholar
  70. 70.
    Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016;142(2):471–9.CrossRefGoogle Scholar
  71. 71.
    Azoulay E, et al. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care. 2011;1(1):5.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Darmon M, Azoulay E. Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol. 2009;21(4):318–26.CrossRefGoogle Scholar
  73. 73.
    Sabik JF, et al. Long-term effectiveness of operations for ascending aortic dissections. J Thorac Cardiovasc Surg. 2000;119(5):946–62.CrossRefGoogle Scholar
  74. 74.
    Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411–7.CrossRefGoogle Scholar
  75. 75.
    Dequanter D, et al. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol. 2008;15(11):3268–71.CrossRefGoogle Scholar
  76. 76.
    Li BT, et al. Malignant cardiac tamponade from non-small cell lung cancer: case series from the era of molecular targeted therapy. J Clin Med. 2014;4(1):75–84.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Herrmann J, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular InstituteThe Cleveland Clinic FoundationClevelandUSA
  2. 2.Case Western Reserve University, Lerner College of MedicineClevelandUSA

Personalised recommendations